Contact this trialFirst, we need to learn more about you.
Bruton's Tyrosine Kinase (BTK) Inhibitor
Zanubrutinib for Primary Membranous Nephropathy
Recruiting1 awardPhase 2 & 3
Cincinnati, Ohio
This trial tests zanubrutinib, a medication aimed at reducing kidney damage, in patients with a specific kidney disease. It measures how well it lowers protein in the urine and compares its effectiveness to another drug, tacrolimus. Zanubrutinib is an oral medication approved in Europe for certain conditions and is being reviewed for approval in the United States.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service